# Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II

> **NCT02560935** · PHASE3 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 440 (actual)

## Conditions studied

- Sickle Cell Disease
- Stroke

## Interventions

- **DRUG:** Hydroxyurea (Moderate Dose)
- **DRUG:** Hydroxyurea (Low Dose)

## Key facts

- **NCT ID:** NCT02560935
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-19
- **Primary completion:** 2020-03-03
- **Final completion:** 2020-03-03
- **Target enrollment:** 440 (ACTUAL)
- **Last updated:** 2020-08-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02560935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02560935, "Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02560935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*